Role of Tranexamic Acid in Decreasing Drain Output after Breast Cancer Surgery

ROLE OF PERIOPERATIVE TRANEXAMIC ACID IN REDUCING DRAIN VOLUME AMONG BREAST CANCER PATIENTS UNDERGOING AXILLARY LYMPH NODE DISSECTION: A RANDOMIZED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036108

Enrollment

Registered

2021-09-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: Drug- Tranexamic Acid: Patients undergoing axillary dissection for breast cancer surgery and receiving perioperative tranexamic acid Control Intervention1: No intervention: Patients und

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with biopsy-proven breast malignancy in the age group of 18-70 years. 2.Patients undergoing axillary lymph node dissection along with mastectomy. 3.Patients undergoing axillary lymph node dissection along with BCS with or without major reconstruction 4.Patients undergoing curative surgeries.

Exclusion criteria

Exclusion criteria: 1.Patients undergoing SLNB alone. 2.Patients undergoing simultaneous surgery in other organs along with breast cancer surgery. 3.Advanced breast malignancy with bleeding breast lesions. 4.Pregnant and breastfeeding women. 5.Patients with coronary artery disease. 5.Patients with a history of deep venous thrombosis (DVT). 6.Patients with a history of malignancy other than breast. 7.Patients undergoing resection with residual disease in-situ (R2 resection). 8.Patients who are not giving consent to participate in the study.

Design outcomes

Primary

Measure	Time frame
1. To determine the Role of Perioperative Tranexamic Acid in Reducing Drain Volume among Breast Cancer Patients Undergoing Axillary Lymph Node Dissection.Timepoint: Baseline, 10 days, 20 days, 30 days, Cumulative drain volume till drain removal.	—

Secondary

Measure	Time frame
1. Duration of the axillary drain. 2. Incidence of Seroma formation within 90 days of surgery. 3. Incidence of Surgical Site Infection (SSI) within 90 days of surgery. 4. Usage of Antibiotics. 5. Number of visits to wound clinic within 90 days of surgery. 6. Delay in adjuvant therapy. 7. Incidence of side effects of Tranexamic acid.Timepoint: Baseline, 10 days, 20 days, 30 days and 90 days.	—

Countries

India

Contacts

Public ContactDr G Sravya Deepika

AIIMS Bhubaneswar

dillipmuduly@gmail.com9013072969

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026